Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07191561 · ClinicalTrials.gov registry record
Hepatic Lipid Metabolism-Alcohol Use Disorder
A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Recruiting
- Registry status
- 25
- Enrollment target
NCT07191561 is a clinical trial that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 25 participants.
The verdict
NCT07191561 is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
Study Summary
Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the steatosis has resolved. The hepatic transcriptome will be compared,
Interventions
- DIAGNOSTIC_TEST Liver biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2029-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07191561
The ClinicalTrials.gov registry entry for NCT07191561 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liver biopsy is the first listed.
NCT07191561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07191561 about?
NCT07191561 is a clinical study titled "Hepatic Lipid Metabolism-Alcohol Use Disorder". Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the steatosis has resolved. The hepatic transcriptome will be compared,
What is the current status of trial NCT07191561?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2026-07-15. Estimated completion is 2029-11-30.
What interventions are being tested in trial NCT07191561?
The interventions under investigation include: Liver biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07191561?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.